European Medicines Agency Concerns Prompt Sanofi To Pull Dupixent Indication - Sanofi (NASDAQ:SNY)
Sanofi (NASDAQ:SNY) said it withdrew its Europe regulatory application for Dupixent (dupilumab) to treat adults with moderate-to-severe bullous pemphigoid. The EMA cited unresolved efficacy issues, including failure to meet the primary trial endpoint and limited secondary results, concluding risks outweighed benefits. FDA approved the indication in June 2025. SNY was up 1.58% to $45.11.
How this was made
The 30-second read
Why it matters
EMA concluded the clinical trial did not meet the primary endpoint, secondary outcomes were not robust, improvements were minimal with uncertainty, and real-world data was insufficient; risks outweighed benefits, leading to withdrawal of the European application.
Market read
This is a concrete regulatory setback for an EU label expansion attempt, removing a potential catalyst for Dupixent’s bullous pemphigoid growth in Europe.
What to watch
The article does not quantify financial exposure of this indication, nor does it address whether Sanofi plans a revised submission or additional trials, which could change the medium-term outlook.
Background
Dupixent (dupilumab) was approved by the FDA in June 2025 for adult bullous pemphigoid; Sanofi sought an EU indication expansion but narrowed scope during review.
Ticker impact
Sanofi withdrew its European regulatory application for Dupixent to treat moderate-to-severe bullous pemphigoid after EMA found efficacy and risk issues unresolved.
Near-term downside bias for SNY tied to reduced EU indication upside; longer-term impact depends on pipeline alternatives and other Dupixent indications.
The article states a finalized withdrawal decision after EMA review, citing failure to meet the primary endpoint and insufficient efficacy support versus risks.
Market effects
Highlights regulatory scrutiny risk for dermatology immunology indication expansions in Europe, potentially affecting sentiment around similar trial designs and endpoints.
EU label expansion prospects for Dupixent in bullous pemphigoid are reduced, which can shift expectations for European dermatology prescribing and payer discussions.
US approval already exists, but the EU withdrawal underscores that global label strategies can diverge by region and trial evidence sufficiency.
Counterpoint
The withdrawal is indication-specific; Dupixent’s broader portfolio and other approved uses may limit the overall earnings impact versus the market’s focus on this single expansion.
Key entities
- companySanofi
Withdrew its European regulatory application for Dupixent in moderate-to-severe bullous pemphigoid after EMA concerns.
- drugDupixent (dupilumab)
Sanofi and Regeneron-developed therapy whose EU indication expansion was withdrawn.
- regulatorEuropean Medicines Agency (EMA)
Evaluated the submission and determined efficacy evidence was insufficient relative to risks.
- companyRegeneron Pharmaceuticals
Co-developer of Dupixent; FDA approved the bullous pemphigoid indication in June 2025.
